Continuous, Subcutaneous Apomorphine Infusion (CSAI) for PD: Development of a Phase IV routine practice study to capture the patient, care partner, and healthcare professional experience in the United States
Objective: To develop a Phase IV study that can be used to inform best practice when considering continuous, subcutaneous apomorphine infusion (CSAI) as a treatment…SL-START: A Multicentre Observational Study of Sublingual Apomorphine Titration and Usage Schemes in Routine Practice
Objective: A patient’s early experience with a new medication is critical to medication adherence and overall treatment outcomes. The SL-START study aims to characterize how…Continuous Subcutaneous Apomorphine Infusion (CSAI) Reduces OFF Periods and Extends Periods of GOOD ON Time: Heatmap Analysis of the TOLEDO Study
Objective: Use heatmap analysis to quantify and examine diurnal patterns of OFF and GOOD ON time periods throughout the day, and changes in the number…Efficacy and Safety of Different Apomorphine Formulations for OFF Episodes in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess the efficacy and safety of different apomorphine formulations for managing OFF episodes in Parkinson’s disease (PD) through a systematic review and meta-analysis.…Functional Activity of Apomorphine Relative to Dopamine at Dopamine Receptors: Findings from G Protein Coupled Receptor Biosensor Assays
Objective: Characterize the functional activity of apomorphine relative to dopamine using a modern panel of G protein-coupled receptor biosensor assays. Background: The structural similarity of…Establishing Clinical Education and Patient Support Programs for Continuous Subcutaneous Apomorphine Infusion (CSAI) in the United States
Objective: Establish an educational “Master Class” program to prepare health care providers (HCPs) for CSAI availability in the U.S. and develop educational support for people…European Experience with Long-term Continuous Subcutaneous Apomorphine Infusions at Higher Doses
Objective: Outline European Union (EU) long-term experience with higher doses (≥6 mg/h or ≥100 mg/d) of continuous subcutaneous apomorphine infusion (CSAI). Background: The EU TOLEDO…Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess the safety profiles of inhaled, sublingual, and subcutaneous apomorphine in patients with Parkinson’s disease (PD). Background: Apomorphine is a direct-acting D1/D2 agonist…When Off Can Cost Life: Myocardial Infarction Due to Spontaneous Coronary Dissection as a Catastrophic Manifestation in Advanced Parkinson’s Disease.
Objective: Describe a patient with PD who suffered an acute myocardial infarction during a severe OFF period. Background: Advanced PD is characterized by complications including…Personality may influence the response to apomorphine infusion in Parkinson’s disease patients
Objective: to evaluate the impact of personality on quality-of-life (QoL) amelioration after treatment by Continuous Subcutaneous Apomorphine Infusion (CSAI) in Parkinson’s disease (PD). Background: PD…
- 1
- 2
- 3
- …
- 13
- Next Page »